At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of colon or rectum
- ✓Metastatic disease with at least one measurable lesion
- ✓No prior systemic anticancer therapy for unresectable metastatic colorectal cancer
- ✓Not a candidate for combination chemotherapy with irinotecan or oxaliplatin, or for curative resection
- ✕Prior trifluridine/tipiracil or allergic reaction to similar compounds
- ✕Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- ✕Contraindication to bevacizumab or capecitabine
- ✕Pregnant or lactating female
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).
In Brief
A Phase 2 clinical trial evaluating Trifluridine/tipiracil + bevacizumab and Capecitabine + bevacizumab for Metastatic Colorectal Cancer. Completed, enrolled 154 participants across 57 sites in 12 countries.
Detailed Summary
The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable metastatic colorectal cancer in patients non-eligible for intensive therapy.
Study Details
Timeline
Interventions
Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.